NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 6, 2010, Pages 709-728

  Cairo, Mitchell S ^a   Jordan, Craig T ^b   Maley, Carlo C ^c   Chao, Clifford ^a   Melnick, Ari ^d   Armstrong, Scott A ^e   Shlomchik, Warren ^f   Molldrem, Jeff ^g   Ferrone, Soldano ^h   Mackall, Crystal ⁱ   Zitvogel, Laurence ^j   Bishop, Michael R ⁱ   Giralt, Sergio A ^k   June, Carl H ^l  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c WISTAR INSTITUTE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Yale University School of Medicine ^*  (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Allogeneic stem cell transplant; Biology; Cancer stem cells; Relapse; Resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 HYDROXYNONENAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN; CELASTROL; DASATINIB; DIMETHYLAMINOPARTHENOLIDE; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; HISTONE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IMATINIB; PARTHENOLIDE; PEPTIDOMIMETIC AGENT; RETINOIC ACID; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CLONE; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; GENETIC POLYMORPHISM; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LYMPHOMA; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; POLYPHARMACY; PROMYELOCYTIC LEUKEMIA; PROTEIN METHYLATION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; WHOLE BODY RADIATION;

BIOMEDICAL RESEARCH; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952580739     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.002     Document Type: Review

References (157)

1. Castro M.A., Onsten T.T., de Almeida R.M., Moreira J.C. Profiling cytogenetic diversity with entropy-based karyotypic analysis. J Theor Biol 2005, 234:487-495.
2. Gonzalez-Garcia I., Sole R.V., Costa J. Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA 2002, 99:13085-13089.
3. Harada T., Okita K., Shiraishi K., Kusano N., Kondoh S., Sasaki K. Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res 2002, 62:835-839.
4. Heng H.H., Stevens J.B., Liu G., et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 2006, 208:461-472.
5. Maley C.C., Galipeau P.C., Finley J.C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473.
6. Murphy D.S., Hoare S.F., Going J.J., et al. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst 1995, 87:1694-1704.
7. Tsao J.L., Yatabe Y., Salovaara R., et al. Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci USA 2000, 97:1236-1241.
8. Varley K.E., Mutch D.G., Edmonston T.B., Goodfellow P.J., Mitra R.D. Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Res 2009, 37:4603-4612.
9. Attolini C.S., Michor F. Evolutionary theory of cancer. Ann N Y Acad Sci 2009, 1168:23-51.
10. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6:924-935.
11. Pepper J.W., Findlay C.S., Kassen R., Spencer S.L., Maley C.C. Cancer research meets evolutionary biology. Evolut Appl 2009, 2:62-70.
12. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-1029.
13. Shah N.P., Skaggs B.J., Branford S., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562-2569.
14. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
15. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59:2511-2515.
16. Wang T.L., Diaz L.A., Romans K., et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004, 101:3089-3094.
17. Carman M.D., Schornagel J.H., Rivest R.S., et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 1984, 2:16-20.
18. Curt G.A., Carney D.N., Cowan K.H., et al. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 1983, 308:199-202.
19. Horns R.C., Dower W.J., Schimke R.T. Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol 1984, 2:2-7.
20. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406.
21. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
22. Michor F., Hughes T.P., Iwasa Y., et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
23. Seliger B. Strategies of tumor immune evasion. BioDrugs 2005, 19:347-354.
24. Carrick S., Parker S., Wilcken N., Ghersi D., Marzo M., Simes J. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005, CD003372.
25. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292:470-484.
26. Cave H., van der Werff ten Bosch J., Suciu S., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998, 339:591-598.
27. Chung N.G., Buxhofer-Ausch V., Radich J.P. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens 2006, 68:371-385.
28. Eckert C., Biondi A., Seeger K., et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001, 358:1239-1241.
29. Radich J.P. The detection and significance of minimal residual disease in chronic myeloid leukemia. Medicina (B Aires) 2000, 60(Suppl 2):66-70.
30. Cosset J.M., Socie G., Dubray B., Girinsky T., Fourquet A., Gluckman E. Single dose versus fractionated total body irradiation before bone marrow transplantation: radiobiological and clinical considerations. Int J Radiat Oncol Biol Phys 1994, 30:477-492.
31. Deeg H.J., Storb R., Longton G., et al. Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity. Int J Radiat Oncol Biol Phys 1988, 15:647-653.
32. Dai Y., Liu M., Tang W., et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 2008, 14:7701-7710.
33. Naumann U., Bahr O., Wolburg H., et al. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Ther 2007, 14:147-161.
34. Shankar S., Srivastava R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004, 7:139-156.
35. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12:228-237.
36. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
37. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991, 77:1660-1665.
38. Acute Radiation Syndrome: A Fact Sheet for Physicians, Centers for Disease Control and Prevention. 2005. Available at: http://www.bt.cdc.gov/radiation/arsphysicianfactsheet.asp.
39. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
40. Vlashi E., McBride W.H., Pajonk F. Radiation responses of cancer stem cells. J Cell Biochem 2009, 108:339-342.
41. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
42. Scharpfenecker M., Kruse J.J., Sprong D., Russell N.S., Ten Dijke P., Stewart F.A. Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells. Int J Radiat Oncol Biol Phys 2009, 73:506-513.
43. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
44. Sims-Mourtada J., Izzo J.G., Ajani J., Chao K.S. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007, 26:5674-5679.
45. Sims-Mourtada J., Izzo J.G., Apisarnthanarax S., et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006, 12:6565-6572.
46. Chen Y.J., Sims-Mourtada J., Izzo J., Chao K.S. Targeting the hedgehog pathway to mitigate treatment resistance. Cell Cycle 2007, 6:1826-1830.
47. Kim J.E., Singh R.R., Cho-Vega J.H., et al. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 2009, 22:1312-1320.
48. Hegde G.V., Peterson K.J., Emanuel K., et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol Cancer Res 2008, 6:1928-1936.
49. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
50. Guan Y., Gerhard B., Hogge D.E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003, 101:3142-3149.
51. Guan Y., Hogge D.E. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 2000, 14:2135-2141.
52. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
53. Hope K.J., Jin L., Dick J.E. Human acute myeloid leukemia stem cells. Arch Med Res 2003, 34:507-514.
54. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:738-743.
55. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005, 5:311-321.
56. Jordan C.T. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 2002, 16:559-562.
57. Jordan C.T., Upchurch D., Szilvassy S.J., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
58. Krivtsov A.V., Twomey D., Feng Z., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
59. Wang J.C.Y., Dorrell C., Ito C.Y., et al. Normal and leukemic human stem cells assayed in immune-deficient mice. Hematopoiesis: A Developmental Approach 2001, 99-118. Oxford University Press, New York. Z. Li (Ed.).
60. Blair A., Hogge D.E., Sutherland H.J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 1998, 92:4325-4335.
61. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
62. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006, 103:16870-16875.
63. Neering S.J., Bushnell T., Sozer S., et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 2007, 110:2578-2585.
64. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
65. Cox C.V., Evely R.S., Oakhill A., Pamphilon D.H., Goulden N.J., Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004, 104:2919-2925.
66. Kong Y., Yoshida S., Saito Y., et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008, 22:1207-1213.
67. le Viseur C., Hotfilder M., Bomken S., et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008, 14:47-58.
68. Bonnet D., Warren E.H., Greenberg P.D., Dick J.E., Riddell S.R. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999, 96:8639-8644.
69. Costello R.T., Mallet F., Gaugler B., et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000, 60:4403-4411.
70. Ishikawa F., Yoshida S., Saito Y., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-1321.
71. Feller N., van der Pol M.A., van Stijn A., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004, 18:1380-1390.
72. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
73. van Rhenen A., Moshaver B., Kelder A., et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007, 21:1700-1707.
74. Nasr R., Guillemin M.C., Ferhi O., et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008, 14:1333-1342.
75. Zhao C., Blum J., Chen A., et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
76. Zhao C., Chen A., Jamieson C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
77. van Stijn A., Kok A., van Stalborch M.A., et al. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. Leukemia 2004, 18:875-877.
78. Wang J.C. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 2007, 1:497-501.
79. Chen W., Kumar A.R., Hudson W.A., et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 2008, 13:432-440.
80. Huntly B.J., Shigematsu H., Deguchi K., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6:587-596.
81. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.
82. Wojiski S., Guibal F.C., Kindler T., et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009, 23:1462-1471.
83. Goessling W., North T.E., Loewer S., et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009, 136:1136-1147.
84. North T.E., Goessling W., Walkley C.R., et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447:1007-1011.
85. Reya T., Duncan A.W., Ailles L., et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423:409-414.
86. Cobas M., Wilson A., Ernst B., et al. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 2004, 199:221-229.
87. Koch U., Wilson A., Cobas M., Kemler R., Macdonald H.R., Radtke F. Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood 2008, 111:160-164.
88. Austin T.W., Solar G.P., Ziegler F.C., Liem L., Matthews W. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 1997, 89:3624-3635.
89. Murdoch B., Chadwick K., Martin M., et al. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc Natl Acad Sci USA 2003, 100:3422-3427.
90. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
91. Malanchi I., Peinado H., Kassen D., et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452:650-653.
92. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
93. Korinek V., Barker N., Morin P.J., et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
94. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
95. Muller-Tidow C., Steffen B., Cauvet T., et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004, 24:2890-2904.
96. Wang C.Z., Yeh Y.C., Tang M.J. DDR1/E-cadherin complex regulates the activation of DDR1 and cell spreading. Am J Physiol Cell Physiol 2009, 297:C419-C429.
97. Huang S.M., Mishina Y.M., Liu S., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
98. Barabe F., Kennedy J.A., Hope K.J., Dick J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 2007, 316:600-604.
99. Wei J., Wunderlich M., Fox C., et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008, 13:483-495.
100. Beachy P.A., Karhadkar S.S., Berman D.M. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004, 432:324-331.
101. Dierks C., Beigi R., Guo G.R., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
102. Berman D.M., Karhadkar S.S., Hallahan A.R., et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002, 297:1559-1561.
103. Johnson R.L., Rothman A.L., Xie J., et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272:1668-1671.
104. Scales S.J., de Sauvage F.J. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009, 30:303-312.
105. Rudin C.M., Hann C.L., Laterra J., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361:1173-1178.
106. Gao J., Graves S., Koch U., et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 2009, 4:548-558.
107. Hofmann I., Stover E.H., Cullen D.E., et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009, 4:559-567.
108. Krivtsov A.V., Feng Z., Lemieux M.E., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
109. Okada Y., Feng Q., Lin Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
110. Schulze J.M., Jackson J., Nakanishi S., et al. Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. Mol Cell 2009, 35:626-641.
111. Villa R., Pasini D., Gutierrez A., et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007, 11:513-525.
112. Goyama S., Nitta E., Yoshino T., et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 2009, 24:81-88.
113. Spensberger D., Delwel R. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 2008, 582:2761-2767.
114. Palomero T., Ferrando A.A. Genomic tools for dissecting oncogenic transcriptional networks in human leukemia. Leukemia 2009, 23:1236-1242.
115. Ci W., Polo J.M., Melnick A. B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr Opin Hematol 2008, 15:381-390.
116. Ci W., Polo J.M., Cerchietti L., et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009, 113:5536-5548.
117. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
118. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
119. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2009.
120. Amabile G., Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med 2009, 15:59-68.
121. Xie H., Ye M., Feng R., Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004, 117:663-676.
122. Majeti R., Becker M.W., Tian Q., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009, 106:3396-3401.
123. Melnick A., Licht J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93:3167-3215.
124. Tallman M.S. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol 2006, 19:311-320.
125. Cattoretti G., Pasqualucci L., Ballon G., et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005, 7:445-455.
126. Huynh K.D., Fischle W., Verdin E., Bardwell V.J. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 2000, 14:1810-1823.
127. Ahmad K.F., Melnick A., Lax S., et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003, 12:1551-1564.
128. Polo J.M., Dell'Oso T., Ranuncolo S.M., et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004, 10:1329-1335.
129. Cerchietti L.C., Yang S.N., Shaknovich R., et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009, 113:3397-3405.
130. Guvench O., MacKerell A.D. Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol 2009, 5:e1000435.
131. Da Silva G.F., Ghetu A., Cerchietti L., et al. Design and development of small molecules for specific targeted therapy of diffuse large B-cell lymphoma. Blood 2007, 110:799.
132. Douvas M., Roudaiya L., Grembecka J., Speck N., Bushweller J.H. Development of allosteric inhibitors of the interaction of AML1 and CBFβ for the treatment of leukemia. Blood 2007, 110:653.
133. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
134. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
135. Bea S., Tort F., Pinyol M., et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001, 61:2409-2412.
136. Griffiths E.A., Gore S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008, 45:23-30.
137. Khan O., La Thangue N.B. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol 2008, 5:714-726.
138. Sansom O.J., Maddison K., Clarke A.R. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol 2007, 4:305-315.
139. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107.
140. Silverman L.R., Verma A., Odchimar-Reissig R., et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium Blood. Blood 2008, 112:3656.
141. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10:295-304.
142. Figueroa M.E., Lugthart S., Li Y., et al. Epigenetic signatures identify new clinically relevant subtypes and define gene regulatory patterns in patients with acute myeloid leukemia (AML). Blood 2008, 112:8768.
143. Figueroa M.E., Skrabanek L., Li Y., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114:3448-3458.
144. Figueroa M.E., Reimers M., Thompson R.F., et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008, 3:e1882.
145. Lugthart S, Figueroa ME, Valk PJM, et al. Two different EVI1 expressing poor-risk AML subgroups with distinct epigenetic signatures uncovered by genome wide DNA methylation profiling Blood. 2008;112:757.
146. Gaymes T.J., Padua R.A., Pla M., et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?. Mol Cancer Res 2006, 4:563-573.
147. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008, 28:752-771.
148. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002, 99:16220-16225.
149. Xu Q., Thompson J.E., Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005, 106:4261-4268.
150. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
151. Guzman M.L., Rossi R.M., Neelakantan S., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
152. Guzman M.L., Li X., Corbett C.A., et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007, 110:4436-4444.
153. Hassane D.C., Guzman M.L., Corbett C., et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008, 111:5654-5662.
154. Konopleva M., Contractor R., Tsao T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
155. Feuring-Buske M., Frankel A.E., Alexander R.L., Gerhard B., Hogge D.E. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002, 62:1730-1736.
156. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
157. Jin L., Lee E.M., Ramshaw H.S., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.